Empowering precision therapeutics with comprehensive genomic insights
Partner with us to gain the most complete view of the genetics of your disease of interest to drive informed decision-making throughout the entire drug development life cycle.
Leverage our expertise to build a complete, reliable foundation of evidence prior to entering the most expensive and time-consuming phases of drug development.
Target and Indication Selection
Enhance your confidence in the targets and indications you select with customizable, thorough reports that answer your most pressing questions, including the extent of existing preclinical work, the characteristics of your target patient population, and more.
Indication Expansion
Expand indications for existing targeted therapeutics based on complete evidence with a customizable, thorough evaluation of the applicable pathway, mechanism, related indications, and more.
Market Assessment
Genomenon’s evidence-based disease prevalence estimates inform market assessment. This data helps pharmaceutical companies understand the patient population and potential market size.
Leverage our expertise and leading software to ensure rapid access to the evidence you need to progress your program through clinical development.
Trial Eligibility and CDx
Expand and refine your inclusion criteria and companion diagnostics, and speed trial enrollment through rapid access to complete genetic evidence.
Genotype-Phenotype Analysis
Strengthen your understanding of genotype-phenotype correlations and enhance your trial design with complete knowledge of published patients alongside their demographics, clinical presentation, and full genotype.
Diagnostic Yield and Awareness
Enhance diagnostic yield and awareness of your disease of interest by granting our network of 2000+ clinical labs access to expertly-curated evidence that accelerates and ensures the completeness of genetic test results.
Genetic Disease Sponsorship - Leverage our expansive network to enhance diagnostic yield and continue to build awareness, even beyond approval.
Enhance Diagnostic Yield and Awareness
Enhance diagnostic yield and awareness of your disease of interest by granting our network of 2,000+ clinical labs access to expertly-curated evidence that accelerates and ensures the completeness of genetic test results.
Research & Development
Preclinical & Phase 1
Phase 2-3
Post Market
Impacting Top Research Institutions and Hospitals
Case Studies
How Pharming is Partnering with Genomenon to Democratize Access to Genetic Evidence and Promote Earlier APDS Diagnosis
Learn how Pharming is using Genomenon’s Genetic Disease Sponsorship program to improve diagnostic rates for an ultra-rare genetic disorder.
How Loxo@Lilly Partnered with Genomenon to Refine the CDx Submission for Retevmo®
Learn how Loxo leveraged Genomenon’s custom genomic services to ensure the actionability of all mutations included on their CDx submission to the PMDA.
How Inozyme is Partnering with Genomenon to Raise Awareness and Promote Earlier Diagnosis of ENPP1 Deficiency
Learn how Inozyme is leveraging Genomenon’s custom genomic services to improve diagnostic rates for an ultra-rare genetic disorder.
Advancing Fabry Disease Diagnosis
Learn how Genomenon curated a comprehensive variant landscape for Fabry disease, enabling Amicus Therapeutics to expand their FDA label and improve patient access to treatment.
Trusted by Industry Leaders Including
Our Offerings For Precision Therapeutics
Find out how we can help your organization.
